LISA42 info

dianetavegia

Published research demonstrates that colorectal cancers with mutated KRAS genes do not respond to anti-EGFR monoclonal antibodies such as Erbitux®. However, researchers believe that Imprime PGG® uses the body's own immune system by engaging a type of white blood cell called the neutrophil to fight cancer cells that are coated with antibodies like Erbitux. Such a strategy might be effective against tumors regardless of whether KRAS is mutated or not. Preclinical studies indicate that Imprime PGG® in combination with Erbitux® can reduce tumor growth.

The open-label, 56-patient KRAS-mutated colorectal cancer study is being conducted at three U.S. locations. Patient enrollment begins this week. All subjects will receive Imprime PGG® at 4 mg/kg weekly plus standard doses of Erbitux®. Tumor measurements and determination of tumor responses for this study will be performed according to Response Evaluation Criteria in Solid Tumors (RECIST)

Click to read

lisa42

Thanks Diane
Thanks, Diane! I read and printed the article, and will take it to my Dr's appts this week. (I was supposed to have seen my regular onc yesterday, but he called in sick and he's now seeing the missed patients all tomorrow).
The idea of Erbitux possibly still helping another compound to work is intriguing. I had such a horrid acne rash reaction to the Erbitux, though- the worst case my oncololgy office had ever seen- that I don't ever want to experience that again. I literally looked like a monster and I have pock marks and scars from it, as well as a tendency to still have acne break outs all the time. That may sound petty, but it was really awful.
Still, everything is worth looking into.
Thanks and have a good day, Diane!

Lisa

luv3jay

Hey Lisa and Diane!
I too am
Hey Lisa and Diane!

I too am KRAS mutant and my onc wanted to enroll me in this clinical trial right before we found out that I was eligible for surgery. Lisa, please do look into this treatment.

-Sheri